Deepnoid, Leading Generative and Physical AI... Proves Clinical Efficacy of 'M4CXR' and Expects Benefits from Government AI Policy

[Financial News]  Deepnoid is gaining attention as a demonstration-based company under the new government's policy to foster Physical AI, based on its technological prowess in developing generative-based medical AI software.
According to Deepnoid on the 14th, the company is proving the field applicability of generative AI through its generative AI-based CXR draft report generation model 'M4CXR'. This solution autonomously processes the entire process from image input to draft report generation with AI, securing effectiveness and usability in real clinical environments.
Previously, in June at ESTI 2025 (European Society of Thoracic Imaging Conference), three related studies were accepted as abstracts, and one of them won the Best Oral Presentation Award, gaining international recognition for its technological prowess.
The government views Physical AI as a core technology to promote the digital transformation of real industries such as manufacturing, logistics, construction, and healthcare, and has allocated a budget of 42.6 billion won for the demonstration (POC) of core technologies in Physical AI by 2025.
In particular, at the 'AI G3 Powerhouse New Technology Strategy Breakfast Forum' held recently in the National Assembly, plans for large-scale R&D projects, including Physical AI, were unveiled, and Deepnoid CEO Choi Woo-sik attended as an industry member to share field challenges in the medical and security sectors.
This technological advancement and policy direction are intertwined, increasing market interest in Deepnoid's long-term growth potential.
SK Securities positively evaluated in a report last February, stating, "Deepnoid is a noteworthy company for the popularization potential of generative AI-based medical devices."
Deepnoid is currently preparing for the Ministry of Food and Drug Safety's clinical trial approval (IND) procedure for 'M4CXR' and is focusing on advancing technology for the commercialization of generative AI-based medical devices. Based on this, it plans to expand its application scope to the industrial Physical AI field in the future.
A Deepnoid representative explained, "We are currently accelerating the clinical trial approval process for M4CXR with the Ministry of Food and Drug Safety, and concentrating all company capabilities on the commercialization of generative AI-based medical devices. Based on this, we expect to expand into the industrial Physical AI field in the future."


kakim@fnnews.com Kim Kyung-ah Reporter